The reactivity-driven biochemical mechanism of covalent KRASG12Cinhibitors.
Hansen, R., Peters, U., Babbar, A., Chen, Y., Feng, J., Janes, M.R., Li, L.S., Ren, P., Liu, Y., Zarrinkar, P.P.(2018) Nat Struct Mol Biol 25: 454-462
- PubMed: 29760531 
- DOI: 10.1038/s41594-018-0061-5
- Primary Citation of Related Structures:  
6B0V, 6B0Y - PubMed Abstract: 
Activating mutations in KRAS are among the most common tumor driver mutations. Until recently, KRAS had been considered undruggable with small molecules; the discovery of the covalent KRAS G12C inhibitors ARS-853 and ARS-1620 has demonstrated that it is feasible to inhibit KRAS with high potency in cells and animals ...